TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Add an action for HURA.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Bianco M.D. | President, CEO & Director | 1957 |
| Mr. Dan Dearborn CPA | Executive VP of Finance & CFO | 1967 |
| Mr. Michael Lawman | Co-Founder | NA |
| Ms. Patricia Lawman | Co-Founder | NA |
| Mr. Michael Krsulich | Head of Quality Assurance | NA |
| Ms. Amanda Garofalo | Senior Vice President of Clinical Operations | NA |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.